Imugene Limited Begins Innovative Cancer Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2024
0mins
Source: Business Insider
Imugene Limited's Trial Update: Imugene Limited has initiated dosing for the first patient in its Phase 1 onCARlytics trial, which is part of the OASIS study targeting advanced solid tumors using a CD19-expressing oncolytic virus.
Innovative Treatment Approach: The trial aims to enhance the recognition of difficult-to-treat tumors by existing therapies, potentially providing new treatment options for patients with metastatic cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
